Open access
Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab
S. Kaneko
Naoki Furuya
Y. Sugiura
H. Tsuruoka
Kazuhiro Nishiyama
Honoka Morita
Tomoki Okura
H. Saji
J. Koike
N. Ohike
M. Mineshita
Medicine
Abstract
Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.